14 recruiting, 13 completed, 4 active not recruiting, 4 unknown. 20 Phase 2, 14 Phase 1, 8 Early Phase 1, 2 Not applicable, 1 Phase 3.
Follow gallium Ga 68 dotatate: new trials by email Literature Review of gallium Ga 68 dotatate trials Research Report on gallium Ga 68 dotatate
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Direct Comparison of Ga-68-DOTATATE and Ga-68-DOTATOC Ga-68- DOTATATE, Ga-68-DOTATOC - Meningioma | Phase 2 | Withdrawn | Weill Medical College of Cornell University | 2026-08-01 | 2026-08-31 | |
| 177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer Biopsy, Biospecimen Collection, Computed Tomography - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma | Phase 2 | Recruiting | OHSU Knight Cancer Institute | 10 | 2026-06-30 | 2026-06-05 |
| Ultralow Dose PET Imaging of SSTR2 Radiotracer Uptake 68Ga-Dotatate - Healthy (Controls), Healthy Volunteers | Phase 2 | Recruiting | Akiva Mintz | 200 | 2025-12-11 | 2026-04-08 |
| RYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma Actinium Ac 225 DOTATATE RYZ101, Biospecimen Collection, Computed Tomography - Recurrent Meningioma | Phase 1 / Phase 2 | Recruiting | Joshua Palmer | 30 | 2025-11-12 | 2026-08-13 |
| Combination External Radiation and PRRT for Large GI Neuroendocrine Tumors. Stereotactic Body Radiation Therapy, Lutetium Lu 177 Dotatate, Computed Tomography - Digestive System Neuroendocrine Tumor, Unresectable Digestive System Neuroendocrine Neoplasm | Phase 1 | Recruiting | Emory University | 15 | 2025-10-14 | 2026-03-02 |
| [212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers [212Pb]VMT-alpha-NET, [203Pb]VMT-alpha-NET, 68Ga-DOTATATE - Sinonasal Neuroendocrine Carcinoma, Nasopharyngeal Carcinoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 120 | 2025-08-19 | 2026-10-06 |
| Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy 68Ga-DOTATATE, [203Pb]VMT-alpha-NET, [212Pb]VMT-alpha-NET - Somatostatin Receptor Positive, Gastrointestinal Neuroendocrine Tumors | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 66 | 2025-02-07 | 2026-10-16 |
| 61Cu-NODAGA-LM3 PET/CT for the Detection of Neuroendocrine Tumors (COPPER PET in NET) 61Cu-NODAGA-LM3, Comparator - Neuroendocrine Tumors | Phase 1 / Phase 2 | Recruiting | University Hospital, Basel, Switzerland | 27 | 2025-02-05 | 2025-05-30 |
| NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer. [68Ga]Ga-PSMA-11, [68Ga]GA-DOTA-TATE, [68Ga]Ga-NeoB - Metastatic Neuroendocrine Prostate Cancer | Phase 1 | Active not recruiting | Novartis Pharmaceuticals | 31 | 2024-07-29 | 2026-10-15 |
| Evaluate the Diagnostic Efficacy, Pharmacokinetics and Safety of 68Ga-DOTATATE Injection PET/CT in NETs 68Ga-DOTATATE Injection - NETs | Phase 3 | Active not recruiting | HTA Co., Ltd. | 95 | 2024-01-08 | 2025-08-13 |
| Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells Biospecimen Collection, Computed Tomography, Gallium Ga 68-DOTATATE - Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation, Metastatic Prostate Neuroendocrine Carcinoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 35 | 2023-12-27 | 2026-10-14 |
| Head-to-head Study of 68Ga-MGS5 Versus 68Ga-DOTATATE PET/CT in Patients With Medullary Thyroid Carcinoma 68Ga-MGS5 - Medullary Thyroid Carcinoma | Phase 1 | Unknown | First Affiliated Hospital of Fujian Medical University | 20 | 2023-06-21 | 2024-07-25 |
| A Head-to-head Comparison of [68Ga]Ga-FAPI and [68Ga]Ga-TATE PET/CT in Patients With Nasopharyngeal Carcinoma: a Single-center, Prospective Study 68Ga-DOTATATE and 68Ga-FAPI - Tumor Positron-Emission Tomography | Phase 1 / Phase 2 | Completed | First Affiliated Hospital of Fujian Medical University | 38 | 2022-11-20 | 2024-02-26 |
| 18F-MFBG PET/CT in the Evaluation of Neural Crest Tumor 18F-MFBG, 68Ga-Dotatate - Neuroendocrine Tumor, Neuroblastoma | Early Phase 1 | Recruiting | Peking Union Medical College Hospital | 150 | 2021-09-01 | 2024-03-01 |
| Study of PRRT in Metastatic, WHO Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery Lutathera, Gallium 68 Dotatate, Computed Tomography (CT) - Gastroenteropancreatic Neuroendocrine Tumor | Phase 1 | Active not recruiting | Stanford University | 10 | 2021-03-17 | 2026-08-12 |
| Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors 68-Gallium DOTATATE - VHL Pancreatic Neuroendocrine Tumors, Von Hippel-Lindau Disease | Phase 2 | Recruiting | National Cancer Institute (NCI) | 740 | 2020-06-02 | 2026-10-16 |
| Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy Gallium Ga 68-DOTATATE, Lutetium Lu 177 Dotatate, Magnetic Resonance Imaging - Grade 1 Meningioma, Grade 2 Meningioma | Phase 2 | Recruiting | Mayo Clinic | 42 | 2020-04-14 | 2026-10-13 |
| Application of 68Ga-DOTA-TATE and 68Ga-DOTA-JR11 PET/CT in the Diagnosis and Evaluation of TIO 68Ga-Dotatate, 68Ga-DOTA-JR11 - Tumor-Induced Osteomalacia | Phase 1 | Unknown | Peking Union Medical College Hospital | 50 | 2020-03-15 | 2021-01-05 |
| Use of 68Ga-dotatate PET Scan in Neuroendocrine Carcinoma of the GI Tract 68Ga-DOTATATE, Positron Emission Tomography (PET) Scan - Neuroendocrine Carcinoma | Completed | H. Lee Moffitt Cancer Center and Research Institute | 30 | 2019-09-25 | 2026-03-31 | |
| An Investigational Scan (68Ga-DOTATATE PET/CT) in Diagnosing Pediatric Metastatic Neuroendocrine Tumors Computed Tomography, Gallium Ga 68-DOTATATE, Positron Emission Tomography - Ganglioneuroblastoma, Ganglioneuroma | Early Phase 1 | Active not recruiting | Mayo Clinic | 20 | 2019-09-23 | 2026-03-31 |
Showing 20 of 42. Sign in to see all of them.
Neuroendocrine Tumors (13) · Meningioma (6) · Carcinoid Tumor (5) · Neuroblastoma (5) · Paraganglioma (5) · Pheochromocytoma (4) · Medulloblastoma (3) · von Hippel-Lindau Disease (3) · Carcinoma, Neuroendocrine (2) · Gastro-enteropancreatic neuroendocrine tumor (2) · Multiple Endocrine Neoplasia Type 1 (2) · Neuroectodermal Tumors, Primitive (2) · Oncogenic osteomalacia (2) · Prostatic Neoplasms (2) · Adenocarcinoma, Follicular (1)
National Cancer Institute (NCI) (6) · Peking Union Medical College Hospital (4) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (3) · Sue O'Dorisio (3) · Emory University (2) · First Affiliated Hospital of Fujian Medical University (2) · M.D. Anderson Cancer Center (2) · Mayo Clinic (2) · Stanford University (2) · Akiva Mintz (1) · Andrei Iagaru (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · HTA Co., Ltd. (1) · Jonsson Comprehensive Cancer Center (1) · Joshua Palmer (1)
United States (34) · China (7) · France (1) · Germany (1) · Spain (1) · Switzerland (1) · United Kingdom (1)
Frank I Lin, M.D. (3) · Andrei Iagaru (2) · Naris Nilubol, M.D. (2) · Brendan C Visser, MD (1) · Ebrahim Delpassand, MD (1) · Fang Li (1) · Fang Li, MD (1) · Guillaume Nicolas, Dr. (1) · Homer A Macapinlac, MD (1) · Hongli Jing, MD (1) · Jana Ivanidze, MD/Ph.D (1) · Jason M Johnson (1) · Joanna Klubo-Gwiezdzinska, M.D. (1) · Johannes Czernin, MD (1) · John M Floberg (1)
PMID 28153957, PMID 29181270, PMID 33551992, PMID 34146130, PMID 35280786, PMID 37160439, PMID 37886645, PMID 39500789, PMID 40717185
2023 (2), P30CA086862 (2), P30CA138292 (1), R01CA167632 (1), UM1CA186691 (1)